Biogen Inc. (BIIB) Earns Market Perform Rating from BMO Capital Markets
's stock had its "market perform" rating reaffirmed by stock analysts at BMO Capital Markets in a research report issued on Sunday. They presently have a $287.00 target price on the biotechnology company's stock.
from Biotech News
0 Comments